Jun 12, 2006
Hemispherx Biopharma Advances Influenza Vaccine/Immunopotentiation Clinical Trials Designed to Increase Vaccine Dosage Supply and Increase Cross-Protection

Jun 05, 2006
HEMISPHERX BIOPHARMA Files Amended 10-K for 2005 and Announces Restatement of Financials for 2003 and 2004

May 15, 2006
Hemispherx Biopharma Announces Influenza Vaccine/Immunopotentiation Clinical Trials Designed to Increase Vaccine Dosage Supply and Increase Cross-Protection

May 12, 2006
Hemispherx Announces Approval by AMEX of Plan to Achieve Compliance Status

May 03, 2006
Hemispherx Biopharma to Present Audited Results of Ampligen® Clinical Trials on Chronic Fatigue Syndrome at 5th International Conference on HHV; Studies Show Medically Significant Improvements Among CFS Patients

Apr 25, 2006
Hemispherx Biopharma Announces Retention of New Senior Personnel and Contractors Ahead of Key NDA Filing for Chronic Fatigue Syndrome Treatment

Apr 13, 2006
Letter to Shareholders of Hemispherx Biopharma, Inc. from William A. Carter, M.D., Chairman of the Board and Chief Executive Officer

Apr 11, 2006
HEMISPHERX BIOPHARMA TO HOST CONFERENCE CALL TO REVIEW COMPANY'S ACCOMPLISHMENTS, UPDATE ON INFLUENZA RELATED STUDIES AND OUTLINE FUTURE GOALS

Apr 07, 2006
Hemispherx Biopharma, Inc. Late Filing of Form 10-K Generates Standard Non-Compliance Notification From The AMEX

Apr 03, 2006
Hemispherx Biopharma, Inc. Announces Delay in Filing Its Form 10-K for the Fiscal Year Ended December 31, 2005

 52   53   54   55   56     57    58   59   60   61   62